SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 26th, 2024 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
The undersigned (the “Holder”) hereby requests that the federal securities law restrictive legend be removed from the book entries representing _________ of shares of common stock, par value $0.0001 per share (the “Shares”), of Cidara Therapeutics, Inc. (the “Company”). In connection with the legend removal, Holder hereby represents to, and agrees with, you as follows:
FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCKWarrant Agreement • November 26th, 2024 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Warrant is one of a series of similar warrants issued pursuant to that certain Securities Purchase Agreement, dated November 20, 2024, by and among the Company and the Investors identified therein (the “Purchase Agreement”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 26th, 2024 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 20, 2024, is entered into by and among Cidara Therapeutics Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
